Visiting Professors: Lung Cancer Edition — Part 1: Our
discussion with Drs Levy and Lobins highlights the following topics
as well as cases from Dr Lobins’s practice:
Case: A man in his early 60s, a current
smoker, with metastatic lung adenocarcinoma and a PD-L1 tumor
proportion score (TPS) of 80% experiences a dramatic response to
first-line pembrolizumab but a recurrence of small lymphocytic
lymphoma (SLL) during therapy (00:00)
Activity and tolerability of immune checkpoint inhibitors alone
or with chemotherapy as first-line therapy in patients with
metastatic non-small cell lung cancer (NSCLC) (02:30)
Duration of therapy with immune checkpoint inhibitors
(05:28)
Perspectives on the effects of recent advances in the
management of lung cancer on the practice of oncology (09:16)
Potential correlation between recurrence of chronic lymphocytic
leukemia or SLL and treatment with anti-PD-1/PD-L1 antibodies
(11:02)
Case: A woman in her late 50s with a history
of autoimmune uveitis is diagnosed with NSCLC and multiple
metastases in the brain (13:46)
Side effects associated with whole-brain radiation therapy
(14:55)
Use of immune checkpoint inhibitors for patients with
preexisting autoimmune disorders (17:45)
Therapeutic options for patients with metastatic NSCLC in the
second-line setting (22:05)
Results of the Phase III REVEL trial investigating ramucirumab
with docetaxel as second-line therapy for patients with metastatic
NSCLC (24:16)
Activity of ramucirumab in patients with squamous cell NSCLC
and those with prior exposure to bevacizumab (25:45)
Side effects and tolerability of ramucirumab and bevacizumab
(26:46)
Case: A man in his early 50s, a current
smoker, with metastatic lung adenocarcinoma and a BRAF non-V600E
tumor mutation receives first-line
carboplatin/pemetrexed/pembrolizumab (29:19)
Hemoptysis as a presenting symptom of lung cancer (30:28)
Clinical care of patients with metastatic NSCLC and no
identified targetable tumor mutations (32:58)
Novel agents and approaches under investigation for lung cancer
(36:11)
Mechanisms of resistance to immunotherapy (39:15)
Monitoring for immune-related adverse events in patients
receiving immune checkpoint inhibitors (41:31)
Case: A woman in her mid-50s with large cell
neuroendocrine carcinoma of the lung and a solitary metastasis in
the brain (43:20)
Perspective on the management of oligometastatic disease
(45:55)
Therapeutic options for patients with metastatic large cell
neuroendocrine carcinoma of the lung (48:10)
Management of metastatic small cell lung cancer in the
second-line setting (51:07)
Case: A man in his early 80s with severe
pulmonary fibrosis is diagnosed with metastatic NSCLC
(54:40)
Challenges in the management of pulmonary fibrosis in elderly
patients with lung cancer (58:22)
Biologic rationale for and emerging data with immune checkpoint
inhibitors in combination with anti-angiogenic agents
(1:01:13)
Benefits and challenges of integrating early palliative care
into the management of metastatic lung cancer (1:03:55)
Case: A man in his late 60s with metastatic
NSCLC with KRAS and p53 tumor mutations experiences disease
progression on multiple lines of therapy (1:06:27)
Therapeutic approach for patients with metastatic NSCLC in the
late-line setting (1:08:26)
Case: A woman in her early 20s initially
diagnosed with unresectable Stage III NSCLC with mutations in ROS1
and p53 develops metastatic disease (1:13:22)
Activity and tolerability of crizotinib and lorlatinib in
patients with metastatic NSCLC and ROS1 tumor mutations
(1:15:37)
Sequencing therapies for patients with metastatic NSCLC and
ROS1 tumor mutations (1:18:23)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.